バイオ医薬品受託製造市場の主要企業には、ロンザ(スイス)、サーモフィッシャーサイエンティフィック社(米国)、ウーシーバイオロジクス社(中国)、キャタレント社(米国)、サムスンバイオロジクス社(韓国)、ベーリンガーインゲルハイムインターナショナルGmbH(ドイツ)、富士フイルムホールディングス株式会社(日本)、アッヴィ社(米国)、ユーロフィンサイエンティフィック社(ルクセンブルク)、ジェンスクリプトバイオテックコーポレーション(米国)、AGC社(日本)、メルク社(ドイツ)、JSR株式会社(日本)、IDTバイオロジカ社(ドイツ)、 味の素バイオファーマ(日本)、アジレントテクノロジーズ社(米国)、旭化成株式会社(日本)
目次
TABLE OF CONTENTS
1 INTRODUCTION
1.1 STUDY OBJECTIVES
1.2 MARKET DEFINITION
1.3 STUDY SCOPE
1.3.1 MARKET SEGMENTATION & REGIONAL SCOPE
1.3.2 INCLUSIONS & EXCLUSIONS
1.3.3 YEARS CONSIDERED
1.4 CURRENCY CONSIDERED
1.5 STAKEHOLDERS
1.6 SUMMARY OF CHANGES
2 RESEARCH METHODOLOGY
2.1 RESEARCH DATA
2.1.1 SECONDARY DATA
2.1.1.1 Objectives of secondary research
2.1.1.2 Key data from secondary sources
2.1.2 PRIMARY DATA
2.1.2.1 Breakdown of primaries (supply- and demand-side participants)
2.1.2.2 Key objective of primary research
2.2 MARKET ESTIMATION
2.2.1 GLOBAL MARKET ESTIMATION
2.2.1.1 Company revenue analysis (bottom-up approach)
2.2.1.1.1 Revenue share analysis of Thermo Fisher Scientific Inc.
2.2.1.2 MnM repository analysis
2.2.1.3 Primary interviews
2.2.2 INSIGHTS OF PRIMARY EXPERTS
2.2.3 SEGMENTAL MARKET SIZE ESTIMATION (TOP-DOWN APPROACH)
2.3 MARKET GROWTH RATE PROJECTIONS
2.4 DATA TRIANGULATION
2.5 STUDY ASSUMPTIONS
2.6 RESEARCH LIMITATIONS
2.7 RISK ANALYSIS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
4.1 BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET OVERVIEW
4.2 NORTH AMERICA: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY SCALE OF OPERATION AND COUNTRY (2025)
4.3 BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET SHARE, BY THERAPEUTIC AREA, 2025 VS. 2030
4.4 BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY MOLECULE TYPE, 2025 VS. 2030 (USD MILLION)
4.5 BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES
5 MARKET OVERVIEW
5.1 INTRODUCTION
5.2 MARKET DYNAMICS
5.2.1 DRIVERS
5.2.1.1 Increasing outsourcing of biologics manufacturing among biopharmaceutical companies
5.2.1.2 Rising demand for biologics and biosimilars
5.2.1.3 Growing focus on personalized medicine
5.2.1.4 Increasing collaborations between pharmaceutical companies and biologics CMOs
5.2.1.5 Advancements in manufacturing technologies
5.2.2 RESTRAINTS
5.2.2.1 Intellectual property rights issues
5.2.3 OPPORTUNITIES
5.2.3.1 Rising demand for cell & gene therapy
5.2.3.2 Significant growth opportunities offered by emerging countries
5.2.3.3 Expansion of biologics manufacturing capacities by CMOs
5.2.4 CHALLENGES
5.2.4.1 Strict regulations
5.3 TECHNOLOGY ANALYSIS
5.3.1 KEY TECHNOLOGIES
5.3.1.1 Single-use technologies
5.3.1.2 Continuous bioprocessing
5.3.2 COMPLEMENTARY TECHNOLOGIES
5.3.2.1 Robotics and automation in fill-finish
5.3.2.2 CRISPR & gene editing tools
5.3.3 ADJACENT TECHNOLOGIES
5.3.3.1 3D bioprinting & microfluidics
5.3.3.2 Biosensors & real-time analytics
5.4 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS' BUSINESSES
5.5 PRICING ANALYSIS (QUALITATIVE)
5.6 VALUE CHAIN ANALYSIS
5.7 ECOSYSTEM ANALYSIS
5.8 PATENT ANALYSIS
5.9 REGULATORY ANALYSIS
5.9.1 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
5.9.2 REGULATORY LANDSCAPE
5.10 KEY CONFERENCES & EVENTS, 2025-2026
5.11 PORTER'S FIVE FORCES ANALYSIS
5.11.1 THREAT OF NEW ENTRANTS
5.11.2 THREAT OF SUBSTITUTES
5.11.3 BARGAINING POWER OF SUPPLIERS
5.11.4 BARGAINING POWER OF BUYERS
5.11.5 INTENSITY OF COMPETITIVE RIVALRY
5.12 KEY STAKEHOLDERS & BUYING CRITERIA
5.12.1 KEY STAKEHOLDERS IN BUYING PROCESS
5.12.2 BUYING CRITERIA
5.13 INVESTMENT & FUNDING SCENARIO
5.14 IMPACT OF AI/GEN AI ON BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET
5.15 IMPACT OF 2025 US TARIFFS ON BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET
5.15.1 INTRODUCTION
5.15.2 KEY TARIFF RATES
5.15.3 PRICE IMPACT ANALYSIS
5.15.4 IMPACT ON COUNTRY/REGION
5.15.4.1 US
5.15.4.2 Europe
5.15.4.3 APAC
5.15.5 IMPACT ON UPSTREAM INDUSTRIES
6 BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY SERVICE
6.1 INTRODUCTION
6.2 MANUFACTURING
6.2.1 SHIFT TOWARD CONTINUOUSLY IMPROVING SINGLE-USE TECHNOLOGIES TO DRIVE MARKET
6.3 FORMULATION & FILL-FINISH
6.3.1 CRITICAL ROLE OF FORMULATION & FILL-FINISH IN BIOLOGICS MANUFACTURING TO DRIVE MARKET GROWTH
6.4 PACKAGING & LABELING
6.4.1 IMPORTANCE OF PACKAGING & LABELING IN ENSURING SAFETY AND EFFECTIVENESS TO SUPPORT MARKET GROWTH
6.5 OTHER SERVICES
7 BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY TYPE
7.1 INTRODUCTION
7.2 BIOLOGIC DRUG SUBSTANCE MANUFACTURING
7.2.1 INCREASING DEMAND FOR BIOTECHNOLOGY PRODUCTS TO DRIVE MARKET
7.3 BIOLOGIC DRUG PRODUCT MANUFACTURING
7.3.1 INCREASING R&D COST AND PROCESS COMPLEXITY TO DRIVE DEMAND FOR CONTRACT MANUFACTURING FOR BIOLOGIC DRUG PRODUCTS
8 BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY SCALE OF OPERATION
8.1 INTRODUCTION
8.2 COMMERCIAL OPERATIONS
8.2.1 INCREASING APPROVALS OF BIOLOGICS TO SUPPORT MARKET GROWTH
8.3 CLINICAL OPERATIONS
8.3.1 INCREASING NUMBER OF CLINICAL TRIALS FOR TARGETED THERAPIES TO DRIVE MARKET
9 BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY SOURCE
9.1 INTRODUCTION
9.2 MAMMALIAN EXPRESSION SYSTEMS
9.2.1 VERSATILE THERAPEUTIC DIVERSITY OF MAMMALIAN EXPRESSION SYSTEMS TO DRIVE MARKET
9.3 NON-MAMMALIAN EXPRESSION SYSTEMS
9.3.1 INCREASING DEMAND FOR BIOLOGICS VACCINES TO SUPPORT MARKET GROWTH
10 BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY MOLECULE TYPE
10.1 INTRODUCTION
10.2 MONOCLONAL ANTIBODIES
10.2.1 GROWING APPROVALS FOR MABS TO PROPEL MARKET
10.3 CELL & GENE THERAPY
10.3.1 INCREASING PREVALENCE OF CHRONIC DISEASES TO DRIVE MARKET
10.4 ANTIBODY-DRUG CONJUGATES
10.4.1 INCREASING INVESTMENTS IN BIOLOGICS TO SUPPORT MARKET GROWTH
10.5 VACCINES
10.5.1 INCREASING DEMAND FOR VACCINES TO DRIVE MARKET
10.6 THERAPEUTIC PEPTIDES & PROTEINS
10.6.1 INCREASING NUMBER OF RESEARCH PROJECTS IN GENOMICS TO SUPPORT MARKET GROWTH
10.7 OTHER MOLECULES
11 BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY THERAPEUTIC AREA
11.1 INTRODUCTION
11.2 ONCOLOGY
11.2.1 INCREASED APPROVALS AND LAUNCH OF BIOLOGICS FOR ONCOLOGY TO DRIVE MARKET
11.3 AUTOIMMUNE DISEASES
11.3.1 RISING PREVALENCE OF AUTOIMMUNE DISEASES TO DRIVE MARKET
11.4 CARDIOVASCULAR DISEASES
11.4.1 DEVELOPMENT OF NEW TREATMENT OPTIONS TO SUPPORT MARKET GROWTH
11.5 METABOLIC DISEASES
11.5.1 INCREASING PREVALENCE OF METABOLIC DISEASES TO DRIVE ADOPTION OF BIOLOGICS
11.6 INFECTIOUS DISEASES
11.6.1 RISING EPIDEMIC OUTBREAKS TO SUPPORT MARKET GROWTH
11.7 NEUROLOGY
11.7.1 HIGH BURDEN OF NEUROLOGICAL DISORDERS TO PROPEL MARKET
11.8 OTHER THERAPEUTIC AREAS
12 BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY REGION
12.1 INTRODUCTION
12.2 NORTH AMERICA
12.2.1 MACROECONOMIC OUTLOOK FOR NORTH AMERICA
12.2.2 US
12.2.2.1 Presence of large number of FDA-approved manufacturing facilities to favor market growth
12.2.3 CANADA
12.2.3.1 Rising government funding for drug development to support market growth
12.3 EUROPE
12.3.1 MACROECONOMIC OUTLOOK FOR EUROPE
12.3.2 GERMANY
12.3.2.1 Rapidly growing pharmaceutical market to drive market
12.3.3 UK
12.3.3.1 Rising investments in drug development to favor market growth
12.3.4 FRANCE
12.3.4.1 Availability of funds from government and private organizations for domestic drug development to support market growth
12.3.5 ITALY
12.3.5.1 Rising commercial drug development pipeline to drive market
12.3.6 SPAIN
12.3.6.1 Rising R&D expenditure to propel market
12.3.7 SWITZERLAND
12.3.7.1 Strong R&D investments and infrastructure expansion to bolster biotech manufacturing
12.3.8 IRELAND
12.3.8.1 Robust R&D growth and CDMO capacity expansion to fuel pharma manufacturing
12.3.9 REST OF EUROPE
12.4 ASIA PACIFIC
12.4.1 MACROECONOMIC OUTLOOK FOR ASIA PACIFIC
12.4.2 CHINA
12.4.2.1 Low manufacturing cost and high demand for medicines to favor market growth
12.4.3 JAPAN
12.4.3.1 Growing demand for biosimilars to drive growth
12.4.4 INDIA
12.4.4.1 Increasing pharma R&D activities and government funding for biotechnology industry to support market growth
12.4.5 SOUTH KOREA
12.4.5.1 Increasing R&D activities for drug development to drive market
12.4.6 REST OF ASIA PACIFIC
12.5 LATIN AMERICA
12.5.1 MACROECONOMIC OUTLOOK FOR LATIN AMERICA
12.5.2 BRAZIL
12.5.2.1 Growing pharmaceutical industry to drive market
12.5.3 MEXICO
12.5.3.1 Regulatory Improvements to support market growth
12.5.4 REST OF LATIN AMERICA
12.6 MIDDLE EAST
12.6.1 MACROECONOMIC OUTLOOK FOR MIDDLE EAST
12.6.2 GCC COUNTRIES
12.6.2.1 Substantial opportunities fueled by strong government support to boost growth
12.6.3 REST OF MIDDLE EAST
12.7 AFRICA
12.7.1 EFFORTS TO IMPROVE LOCAL PHARMACEUTICAL PRODUCTION TO BOOST MARKET
12.7.2 MACROECONOMIC OUTLOOK FOR AFRICA
13 COMPETITIVE LANDSCAPE
13.1 OVERVIEW
13.2 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, 2022-2025
13.3 REVENUE ANALYSIS, 2020-2024
13.4 MARKET SHARE ANALYSIS, 2024
13.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2024
13.5.1 STARS
13.5.2 EMERGING LEADERS
13.5.3 PERVASIVE PLAYERS
13.5.4 PARTICIPANTS
13.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2024
13.5.5.1 Company footprint
13.5.5.2 Region footprint
13.5.5.3 Service type footprint
13.5.5.4 Molecule type footprint
13.5.5.5 Therapeutic area footprint
13.6 COMPANY EVALUATION MATRIX: SMES/STARTUPS, 2024
13.6.1 PROGRESSIVE COMPANIES
13.6.2 RESPONSIVE COMPANIES
13.6.3 DYNAMIC COMPANIES
13.6.4 STARTING BLOCKS
13.6.5 COMPETITIVE BENCHMARKING: SMES/STARTUPS, 2024
13.6.5.1 Detailed list of key SMEs/startups
13.6.5.2 Competitive benchmarking of key emerging players/startups
13.7 COMPANY VALUATION & FINANCIAL METRICS
13.7.1 FINANCIAL METRICS
13.7.2 COMPANY VALUATION
13.8 BRAND/PRODUCT COMPARISON
13.9 COMPETITIVE SCENARIO
13.9.1 SERVICE LAUNCHES
13.9.2 DEALS
13.9.3 EXPANSIONS
14 COMPANY PROFILES
14.1 KEY PLAYERS
14.1.1 LONZA
14.1.1.1 Business overview
14.1.1.2 Services offered
14.1.1.3 Recent developments
14.1.1.3.1 Deals
14.1.1.3.2 Expansions
14.1.1.4 MnM view
14.1.1.4.1 Key strengths
14.1.1.4.2 Strategic choices
14.1.1.4.3 Weaknesses & competitive threats
14.1.2 WUXI BIOLOGICS
14.1.2.1 Business overview
14.1.2.2 Services offered
14.1.2.3 Recent developments
14.1.2.3.1 Deals
14.1.2.3.2 Expansions
14.1.2.4 MnM view
14.1.2.4.1 Key strengths
14.1.2.4.2 Strategic choices
14.1.2.4.3 Weaknesses & competitive threats
14.1.3 SAMSUNG BIOLOGICS
14.1.3.1 Business overview
14.1.3.2 Services offered
14.1.3.3 Recent developments
14.1.3.3.1 Service launches
14.1.3.3.2 Deals
14.1.3.3.3 Expansions
14.1.3.4 MnM view
14.1.3.4.1 Key strengths
14.1.3.4.2 Strategic choices
14.1.3.4.3 Weaknesses & competitive threats
14.1.4 THERMO FISHER SCIENTIFIC INC.
14.1.4.1 Business overview
14.1.4.2 Services offered
14.1.4.3 Recent developments
14.1.4.3.1 Deals
14.1.4.4 MnM view
14.1.4.4.1 Key strengths
14.1.4.4.2 Strategic choices
14.1.4.4.3 Weaknesses & competitive threats
14.1.5 ABBVIE INC.
14.1.5.1 Business overview
14.1.5.2 Services offered
14.1.6 CATALENT, INC.
14.1.6.1 Business overview
14.1.6.2 Services offered
14.1.6.3 Recent developments
14.1.6.3.1 Deals
14.1.6.3.2 Expansions
14.1.6.4 MnM view
14.1.6.4.1 Key strengths
14.1.6.4.2 Strategic choices
14.1.6.4.3 Weaknesses & competitive threats
14.1.7 BOEHRINGER INGELHEIM INTERNATIONAL GMBH
14.1.7.1 Business overview
14.1.7.2 Services offered
14.1.7.3 Recent developments
14.1.7.3.1 Other developments
14.1.8 FUJIFILM HOLDINGS CORPORATION
14.1.8.1 Business overview
14.1.8.2 Services offered
14.1.8.3 Recent developments
14.1.8.3.1 Deals
14.1.8.3.2 Expansions
14.1.9 EUROFINS SCIENTIFIC
14.1.9.1 Business overview
14.1.9.2 Services offered
14.1.9.3 Recent developments
14.1.9.3.1 Expansions
14.1.10 GENSCRIPT BIOTECH CORPORATION
14.1.10.1 Business overview
14.1.10.2 Services offered
14.1.10.3 Recent developments
14.1.10.3.1 Service launches
14.1.10.3.2 Deals
14.1.10.3.3 Expansions
14.1.11 AGC INC.
14.1.11.1 Business overview
14.1.11.2 Services offered
14.1.11.3 Recent developments
14.1.11.3.1 Deals
14.1.11.3.2 Expansions
14.1.12 MERCK KGAA
14.1.12.1 Business overview
14.1.12.2 Services offered
14.1.12.3 Recent developments
14.1.12.3.1 Deals
14.1.12.3.2 Expansions
14.1.13 JSR CORPORATION
14.1.13.1 Business overview
14.1.13.2 Services offered
14.1.13.3 Recent developments
14.1.13.3.1 Expansions
14.1.14 IDT BIOLOGIKA
14.1.14.1 Business overview
14.1.14.2 Services offered
14.1.14.3 Recent developments
14.1.14.3.1 Other developments
14.1.15 AJINOMOTO BIO-PHARMA
14.1.15.1 Business overview
14.1.15.2 Services offered
14.1.15.3 Recent developments
14.1.15.3.1 Deals
14.1.16 AGILENT TECHNOLOGIES INC.
14.1.16.1 Business overview
14.1.16.2 Services offered
14.1.16.3 Recent developments
14.1.16.3.1 Deals
14.1.17 ASAHI KASEI CORPORATION
14.1.17.1 Business overview
14.1.17.2 Services offered
14.1.17.3 Recent developments
14.1.17.3.1 Deals
14.2 OTHER PLAYERS
14.2.1 ONESOURCE PHARMA SOLUTIONS
14.2.2 RECIPHARM AB
14.2.3 EMERGENT BIOSOLUTIONS
14.2.4 SHANGHAI FOSUN PHARMACEUTICAL CO., LTD.
14.2.5 LOTTE BIOLOGICS
14.2.6 CURIA GLOBAL, INC.
14.2.7 POLYPLUS TRANSFECTION
14.2.8 ALDEVRON LLC
14.2.9 MINAPHARM PHARMACEUTICALS
14.2.10 RENTSCHLER BIOPHARMA SE
14.2.11 PORTON PHARMA SOLUTIONS
14.2.12 CELLARES, INC.
14.2.13 MABPLEX INTERNATIONAL CO., LTD.
14.2.14 ASYMCHEM INC.
15 APPENDIX
15.1 DISCUSSION GUIDE
15.2 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
15.3 CUSTOMIZATION OPTIONS
15.4 RELATED REPORTS
15.5 AUTHOR DETAILS n
